Bioresorbable magnesium-based sirolimus-eluting stent versus permanent metallic everolimus-eluting stent in patients with acute coronary syndromes

Fakultní nemocnice Královské Vinohrady0 个研究点目标入组 50 人开始时间: 2021年5月12日最近更新: 2021年9月27日

适应症

试验速览

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34505954/ (added 13/09/2021)

•Patients were included if they presented with:
•1. ST-elevation myocardial infarction (STEMI) <24 hours since the onset of symptoms or
•2. Non-ST-elevation myocardial infarction (non-STEMI) or
•3. Unstable angina caused by thrombotic acute coronary stenosis and coronary artery with stenosis diameter suitable for implantation of both investigated types of stents (vessel diameter between 2.7 and 3.7 mm)

•1. Cardiogenic shock or pulmonary oedema
•2. Expected survival less than 3 years due to severe comorbidities
•3. Contraindication of 12 months dual antiplatelet treatment including an indication to treatment with peroral anticoagulants
•4. Diffuse calcifications or extreme tortuosity of the target vessel
•5. In-stent restenosis or stent thrombosis as the culprit lesion
•6. Left main stenosis

发起方